| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Because the biological characteristics of lung cancer may alter during treatment, it is necessary to clarify the molecular events in each individual at the time of acquired resistance to EGFR-TKI and before re-challenge with EGFR-TKI for selection of the appropriate patient population. However, analyses of biomarkers at those times have not typically been performed because of difficulty obtaining cancer specimens during disease progression. To solve this problem, we chose plasma as the sample for monitoring molecular events related with acquired resistance.
In results our prospective study using plasma, T790M was detected in 40% of patients who acquired resistance to first generation EGFR-TKI and it was comparable level to re-biopsy. With respect to our retrospective study to clarify predictive marker for EGFR-TKI re-challenge, combination of T790M detection and HGF quantification using plasma is a potentially useful assay system for predicting the effect of EGFR-TKI re-challenge.
|
